Genmab — Marts 2012
-
-
hej gentogen har det nogen betydning?
-
genmab regnskab ude nu
-
-
de har stadig over en milliard i cash
-
telefon conference kl 1830
-
jeg holder den i plus chatten, men historikken er gratis
-
------cc Genmab årsrapport 2011 --------
-
David Eatwell og Jan er klar
-
Arzerra har 40% vækst og er lanceret i 23 lande
-
Jan fremhæver head to head mod ritux i DLBCL
-
Nu Zalutumumab - skuffelse men omkostningsbevidst
-
Så Daratumumab
-
Nu skal vi lære noget om det. Benmarvsoptopsi viser respons
-
Data bekræfter at Dara er aktiv
-
Nye studier
-
Så samarbejdet med den hemmelige partner om DUO body
-
fabrikken - we remain highly committed to selling the factory
-
De slog deres egne første og seneste forventninger
-
omsætningen udgøres af 226 deferred + 75 fra arzerra + 50 fra klinisk reimbursement
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind